Drug intelligence / Profile preview

suvicitumab

Development stage: Phase 1
Lead developer: Simcere Pharmaceutical Group
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

Suvicitumab (SIM0235) is a humanized IgG1 monoclonal antibody that targets Tumor Necrosis Factor Receptor 2 (TNFR2), an immune checkpoint molecule highly expressed on regulatory T cells (Tregs) and certain tumor cells. Developed by Simcere Pharmaceutical, suvicitumab functions as a TNFR2 antagonist, blocking the TNF-alpha/TNFR2 signaling pathway to inhibit the suppressive function and proliferation of Tregs within the tumor microenvironment. Additionally, it may promote the depletion of TNFR2-positive cells via antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP). By reducing immune suppression, suvicitumab aims to restore anti-tumor T-cell activity. It is currently in Phase 1 clinical development for patients with advanced solid tumors, including colorectal cancer.

Other names: Anti-TNFR2 monoclonal antibodyAnti-TNFR-2 monoclonal antibodyAnti-TNFR 2 monoclonal antibody

Targets

TNFR2 (Tumor necrosis factor receptor superfamily member 1B)

Beyond the preview

Go deeper on suvicitumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on suvicitumab.

Explore the full profile